Daily Endocrinology Research Analysis
Analyzed 108 papers and selected 3 impactful papers.
Summary
Three mechanistic and translational studies illuminate how metabolic stress interfaces with endocrine systems to drive disease. Hyperglycemia activates vascular senescence via TXNIP; gut-derived TMAO triggers osteoblast senescence through cGAS-STING; and bile acid–induced TBG depletion impairs local thyroxine availability causing trophoblast apoptosis in intrahepatic cholestasis of pregnancy. Each identifies actionable targets with clear translational potential.
Research Themes
- Metabolic-immune signaling driving endocrine complications
- Actionable molecular targets (TXNIP, cGAS-STING, TBG) in vascular, bone, and placental pathology
- Multi-omics and in vivo validation enabling translational endocrinology
Selected Articles
1. TXNIP Is Positioned as a Key Mediator of Hyperglycemia-Induced Vascular Senescence.
Hyperglycemia drives vascular smooth muscle cell senescence through TXNIP under direct transcriptional control by ChREBP. Genetic knockdown in the aorta and pharmacologic TXNIP inhibition or AKT activation reduced arterial stiffness and atherosclerotic burden in diabetic mice, nominating TXNIP as a therapeutic target.
Impact: This study elucidates a precise hyperglycemia–TXNIP–senescence axis and demonstrates in vivo reversibility of vascular aging features, supporting drug development targeting TXNIP signaling in diabetic vasculopathy.
Clinical Implications: TXNIP inhibitors or interventions enhancing AKT signaling could mitigate arterial stiffness and vascular aging in diabetes. TXNIP pathway biomarkers may assist in risk stratification and therapeutic monitoring.
Key Findings
- ChREBP directly activates TXNIP transcription in vascular smooth muscle cells under hyperglycemia.
- Aorta-specific TXNIP knockdown reduced arterial stiffness and atherosclerotic plaque in diabetic mice.
- Pharmacologic TXNIP inhibition or AKT activation ameliorated vascular senescence phenotypes.
Methodological Strengths
- Mechanistic dissection linking a defined transcription factor (ChREBP) to TXNIP in VSMCs
- In vivo validation with aorta-specific knockdown and pharmacologic modulation demonstrating phenotypic rescue
Limitations
- Preclinical models; human interventional data are lacking
- Sample sizes and long-term safety of TXNIP targeting are not described
Future Directions: Translate TXNIP-targeted strategies to early-phase human trials, develop circulating readouts of TXNIP activity, and test combination strategies with standard cardiometabolic therapies.
This study identifies the carbohydrate-responsive element-binding protein as the direct transcriptional activator of TXNIP in vascular smooth muscle cells under conditions of hyperglycemia. Aorta-specific TXNIP knockdown demonstrates therapeutic potential by alleviating arterial stiffness and attenuating atherosclerotic plaque in diabetic mice. Pharmacologic inhibition of TXNIP or activation of AKT ameliorates the senescent phenotype, highlighting a druggable pathway in diabetic vasculopathy.
2. Gut Microbiota-Derived TMAO Drives MC3T3-E1 Senescence and Osteogenic Dysfunction via cGAS-STING-NF-κB Signaling: Implications for Age-Related Bone Loss.
TMAO induces osteoblast senescence, suppresses osteogenic differentiation, and degrades bone microarchitecture via mtDNA release and cGAS–STING–NF-κB activation. Genetic STING knockdown and NF-κB inhibition mitigate these effects, nominating the cGAS–STING pathway as a target for age-related bone loss.
Impact: This work mechanistically connects a gut-derived metabolite to osteoblast senescence and bone loss, highlighting a translatable immunometabolic axis (cGAS–STING) for skeletal aging.
Clinical Implications: Targeting cGAS–STING or modulating TMAO exposure (dietary/microbiome interventions) could form adjunct strategies to preserve bone health in aging and metabolic disease.
Key Findings
- TMAO induced G0/G1 arrest and senescence markers in MC3T3-E1 cells without overt cytotoxicity.
- TMAO suppressed osteogenic differentiation and mineralization and downregulated osteogenic proteins.
- Mechanism involved mtDNA leakage, cGAS–STING activation, and NF-κB signaling; STING knockdown rescued phenotypes and improved bone microarchitecture in vivo.
Methodological Strengths
- Integrated in vitro and in vivo models with genetic (AAV9-STING) and pharmacologic perturbations
- Comprehensive phenotyping including cell cycle, senescence, osteogenesis, signaling, and micro-CT bone analysis
Limitations
- Single osteoblast cell line; human translational data are absent
- Exposure levels and duration relative to human TMAO physiology require clarification
Future Directions: Validate findings in human primary osteoblasts and cohorts linking circulating TMAO with bone turnover and fracture risk; assess cGAS–STING inhibitors in osteopenia models.
Age-related osteoporosis is closely associated with osteoblast dysfunction, in which cellular senescence plays a key role. Trimethylamine N-oxide (TMAO), a gut microbiota-derived metabolite, is implicated in aging and metabolic diseases and has been linked to bone metabolism. However, whether TMAO impairs bone formation by regulating osteoblast senescence remains unclear. This study investigated the effects of TMAO on osteoblast senescence and osteogenic function, focusing on the cGAS-STING-NF-κB signaling axis. MC3T3-E1 cells were treated with TMAO to evaluate proliferation, cell cycle progression, senescence, and osteogenic differentiation. Cytosolic DNA release and activation of the cGAS-STING-NF-κB axis were assessed. In vivo, a chronic TMAO exposure model was established, combined with AAV9-mediated STING knockdown, and bone microarchitecture was analyzed by micro-CT. TMAO significantly inhibited proliferation and induced G0/G1 arrest in MC3T3-E1 cells without apparent cytotoxicity. It increased SA-β-gal-positive cells and upregulated senescence-associated markers, indicating a senescent phenotype. Functionally, TMAO suppressed osteogenic differentiation and mineralization and downregulated osteogenic proteins. Mechanistically, TMAO promoted abnormal release of mitochondrial DNA into the cytosol, activated the cGAS-STING pathway, and enhanced NF-κB signaling. STING overexpression exacerbated, whereas STING knockdown alleviated, TMAO-induced senescence and osteogenic impairment. NF-κB inhibition partially reversed these effects. In vivo, TMAO exposure impaired trabecular and cortical bone microarchitecture, which was partially improved by STING knockdown. TMAO induces osteoblast senescence and impairs osteogenic function, potentially via mtDNA-mediated activation of the cGAS-STING-NF-κB axis. These findings provide insight into age-related bone loss and suggest potential therapeutic targets.
3. Bile acid-induced TBG depletion promotes trophoblast apoptosis via local thyroxine insufficiency in intrahepatic cholestasis of pregnancy.
Multi-omics and cross-platform validation identify disruption of the TBG–T4 axis as a mechanistic driver of placental trophoblast apoptosis in ICP. Clinical associations (lower TBG/T4, earlier delivery, lower birth weight) and rescue by TBG overexpression in vivo support biomarker and therapeutic potential.
Impact: This study bridges endocrine thyroid transport biology with obstetric cholestasis, delivering a mechanistic framework, human associations, and in vivo rescue that collectively advance biomarker discovery and therapeutic hypotheses.
Clinical Implications: Serum TBG (with contextual T4) may improve risk stratification and timing of delivery decisions in ICP. Restoring TBG–T4 availability emerges as a candidate therapeutic strategy, warranting careful clinical translation.
Key Findings
- Multi-omics flagged the TBG–T4 axis as a relevant pathway in ICP.
- Despite physiological ranges, circulating TBG, total T4, and free T4 were significantly reduced across pregnancy in ICP and associated with cholestasis, earlier delivery, and lower birth weight.
- Reduced TBG decreased local T4 and increased trophoblast apoptosis under bile acid stress; Ad‑TBG overexpression restored thyroid homeostasis and improved placental/hepatic injury and fetal outcomes in rats.
Methodological Strengths
- Integrated multi-omics discovery with trimester-specific clinical validation and placental tissue analyses
- Mechanistic confirmation in vitro and therapeutic rescue in an in vivo ICP model
Limitations
- Observational human associations are susceptible to confounding; interventional human data are lacking
- Standardization of TBG assays and external validation across populations are needed
Future Directions: Prospective validation of TBG as a prognostic biomarker, evaluation of thyroid transport therapeutics, and integration into clinical decision algorithms for ICP.
Intrahepatic cholestasis of pregnancy (ICP) is characterized by bile acid accumulation, placental dysfunction, and adverse perinatal outcomes. However, there is currently no reliable tool to predict the occurrence of severe ICP or its associated complications, and its pathophysiology remains incompletely understood. The objective of this study was to identify more sensitive and specific biomarkers for the clinical diagnosis, early prediction, and prognostic assessment of adverse outcomes in ICP, and to explore the biological relevance of the identified pathway at the maternal-fetal interface. We performed integrated serum metabolomic-proteomic analysis, followed by trimester-specific clinical validation, placental tissue analysis, in vitro trophoblast experiments, and in vivo validation in an estrogen-induced ICP rat model. Exploratory multi-omics analysis highlighted the thyroxine-binding globulin-thyroxine (TBG-T4) axis, related to thyroid hormone transport and availability, as a biologically relevant pathway in ICP. Although total and free T4 remained within physiological reference ranges, circulating TBG, total T4, and free T4 were significantly reduced across pregnancy in women with ICP and were associated with biochemical cholestasis, earlier delivery, and lower neonatal birth weight. Mechanistic analyses showed that reduced TBG availability was associated with decreased local T4 availability and enhanced trophoblast apoptosis under bile acid stress. In the ICP rat model, Ad-TBG-mediated TBG overexpression partially restored thyroid hormone homeostasis, attenuated placental and hepatic injury, and improved fetal growth and survival. These findings identify disruption of the TBG-T4 axis as a mechanistic link between cholestatic stress, impaired thyroid hormone availability, and trophoblast apoptosis in ICP.